FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Int Immunopharmacol / Evaluation of the safety, immunogenicity and pharmacokinetic...
International immunopharmacology2007; 7(13); 1834-1840; doi: 10.1016/j.intimp.2007.09.011

Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab’)(2) in macaque.

Abstract: To warrant potential clinical testing, the equine anti-SARS-CoV F(ab')(2) requires evaluation in as many animal models as possible and a safety test in a primate model. In this study, we evaluated the pharmacokinetics, tolerance and immunity of this kind of antibody in macaques and rats. Results showed that the F(ab')(2) fragments had a normal metabolism in injected animals. The general physiological indexes did not differ between animals injected with anti-SARS-CoV F(ab')(2) or saline. However, a mild inflammatory response in local injection site and a moderate immune response against this antibody in the successively injected animals were observed, which however recovered 3 weeks after the last injection. The antibody titring from 1:100 to 400 against the equine anti-SARS-CoV F(ab')(2) in the inoculated hosts could be detected at week 2 during the successive injections of the equine F(ab')(2). The considerable safety of this antibody used in primates and the fact that the immune system of the host can be motivated by post-injection of the F(ab')(2) indicate that this type of anti-SARS-CoV antibody can be used for prevention and treatment of SASR, especially at the early stage of this virus infection. In addition, it can also provide the precious time for the combined use of other anti-SARS-CoV agents such as antiviral drug and vaccine.
Get Full Text
Publication Date: 2007-10-04 PubMed ID: 17996696PubMed Central: PMC7106090DOI: 10.1016/j.intimp.2007.09.011Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research examines the safety, immune response, and how the body processes equine anti-SARS-CoV F(ab’)(2) – an antibody – in macaques and rats, with a focus on the potential for its use in preventing and treating Severe Acute Respiratory Syndrome (SARS), especially in the early stages of infection.

Research Aim and Method

  • This research aimed to evaluate the safety, tolerance, how the body processes the function (pharmacokinetics), and immune response to the equine anti-SARS-CoV F(ab’)(2) antibodies in two animal models, macaques and rats. This was considered important in validating its further testing in clinical trials.
  • The antibody was injected into the animal subjects and physiological changes were monitored over a period of time, comparing to those injected with a saline solution.

Main Findings

  • The results indicated that the F(ab’)(2) fragments had a regular metabolism, meaning that the body processed the antibody normally in the animals that received it. The general physiological parameters between the group of animals injected with anti-SARS-CoV F(ab’)(2) and those injected with saline did not exhibit significant differences.
  • However, a mild inflammation at the injection site and a moderate immune response against the antibody in animals that were successively injected were observed, but these symptoms were shown to recover three weeks after the last injection.
  • The antibody titration from 1:100 to 400 against equine anti-SARS-CoV F(ab’)(2) was observed in the hosts at the second week of consecutive equine F(ab’)(2) injections.

Implications

  • These findings suggested that the equine anti-SARS-CoV F(ab’)(2) antibody could potentially be used for prevention and treatment of SARS, especially at the early stages of viral infection. This is due to the relatively good safety profile demonstrated by the antibody in the primate study.
  • Beyond its direct application, the antibody could also potentially offer valuable time for the combined use of other anti-SARS-CoV interventions, like antiviral drugs and vaccines, thereby enhancing the overall effectiveness of the SARS treatment strategy.

Cite This Article

APA
Xu Y, Jia Z, Zhou L, Wang L, Li J, Liang Y, Zhao T, Ni B, Wu Y. (2007). Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab’)(2) in macaque. Int Immunopharmacol, 7(13), 1834-1840. https://doi.org/10.1016/j.intimp.2007.09.011

Publication

International immunopharmacology
ISSN: 1567-5769
NlmUniqueID: 100965259
Country: Netherlands
Language: English
Volume: 7
Issue: 13
Pages: 1834-1840

Researcher Affiliations

Xu, Yunsheng
  • Department of Dermatology, the First Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, People's Republic of China.
Jia, Zhengcai
    Zhou, Liyun
      Wang, Li
        Li, Jintao
          Liang, Yunfei
            Zhao, Tingting
              Ni, Bing
                Wu, Yuzhang

                  MeSH Terms

                  • Animals
                  • Antibodies, Viral / immunology
                  • Antibodies, Viral / metabolism
                  • Antibodies, Viral / therapeutic use
                  • Antibodies, Viral / toxicity
                  • Horses
                  • Immunoglobulin Fab Fragments / immunology
                  • Immunoglobulin Fab Fragments / metabolism
                  • Immunoglobulin Fab Fragments / therapeutic use
                  • Immunoglobulin Fab Fragments / toxicity
                  • Macaca
                  • Rats
                  • Severe acute respiratory syndrome-related coronavirus / immunology
                  • Severe Acute Respiratory Syndrome / prevention & control
                  • Severe Acute Respiratory Syndrome / therapy

                  References

                  This article includes 25 references
                  1. Bukreyev A, Lamirande EW, Buchholz UJ, Vogel LN, Elkins WR, St Claire M, Murphy BR, Subbarao K, Collins PL. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.. Lancet 2004 Jun 26;363(9427):2122-7.
                    pmc: PMC7112367pubmed: 15220033doi: 10.1016/S0140-6736(04)16501-Xgoogle scholar: lookup
                  2. Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, Subbarao K, Moss B. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice.. Proc Natl Acad Sci U S A 2004 Apr 27;101(17):6641-6.
                    pmc: PMC404098pubmed: 15096611doi: 10.1073/pnas.0401939101google scholar: lookup
                  3. Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, Collins PL. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.. Proc Natl Acad Sci U S A 2004 Jun 29;101(26):9804-9.
                    pmc: PMC470755pubmed: 15210961doi: 10.1073/pnas.0403492101google scholar: lookup
                  4. Yang ZY, Kong WP, Huang Y, Roberts A, Murphy BR, Subbarao K, Nabel GJ. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice.. Nature 2004 Apr 1;428(6982):561-4.
                    pmc: PMC7095382pubmed: 15024391doi: 10.1038/nature02463google scholar: lookup
                  5. Cinatl J Jr, Michaelis M, Hoever G, Preiser W, Doerr HW. Development of antiviral therapy for severe acute respiratory syndrome.. Antiviral Res 2005 Jun;66(2-3):81-97.
                    pmc: PMC7132397pubmed: 15878786doi: 10.1016/j.antiviral.2005.03.002google scholar: lookup
                  6. Peiris JS, Guan Y, Yuen KY. Severe acute respiratory syndrome.. Nat Med 2004 Dec;10(12 Suppl):S88-97.
                    pmc: PMC7096017pubmed: 15577937doi: 10.1038/nm1143google scholar: lookup
                  7. Haagmans BL, Kuiken T, Martina BE, Fouchier RA, Rimmelzwaan GF, van Amerongen G, van Riel D, de Jong T, Itamura S, Chan KH, Tashiro M, Osterhaus AD. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques.. Nat Med 2004 Mar;10(3):290-3.
                    pmc: PMC7095986pubmed: 14981511doi: 10.1038/nm1001google scholar: lookup
                  8. Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases.. Clin Microbiol Rev 2000 Oct;13(4):602-14.
                    pmc: PMC88952pubmed: 11023960doi: 10.1128/CMR.13.4.602google scholar: lookup
                  9. Watt G, Kantipong P, Jongsakul K, de Souza M, Burnouf T. Passive transfer of scrub typhus plasma to patients with AIDS: a descriptive clinical study.. QJM 2001 Nov;94(11):599-607.
                    pubmed: 11704689doi: 10.1093/qjmed/94.11.599google scholar: lookup
                  10. Savoldo B, Goss J, Liu Z, Huls MH, Doster S, Gee AP, Brenner MK, Heslop HE, Rooney CM. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients.. Transplantation 2001 Sep 27;72(6):1078-86.
                    pubmed: 11579304doi: 10.1097/00007890-200109270-00017google scholar: lookup
                  11. Chiba T, Yokosuka O, Goto S, Fukai K, Imazeki F, Shishido H, Narita M, Saisho H. Successful clearance of hepatitis B virus after allogeneic stem cell transplantation: beneficial combination of adoptive immunity transfer and lamivudine.. Eur J Haematol 2003 Sep;71(3):220-3.
                    pubmed: 12930325doi: 10.1034/j.1600-0609.2003.00114.xgoogle scholar: lookup
                  12. Ferrantelli F, Rasmussen RA, Hofmann-Lehmann R, Xu W, McClure HM, Ruprecht RM. Do not underestimate the power of antibodies--lessons from adoptive transfer of antibodies against HIV.. Vaccine 2002 Dec 19;20 Suppl 4:A61-5.
                    pubmed: 12477430doi: 10.1016/s0264-410x(02)00389-4google scholar: lookup
                  13. Dahmen U, Dirsch O, Li J, Fiedle M, Lu M, Rispeter K, Picucci M, Broelsch CE, Roggendorf M. Adoptive transfer of immunity: a new strategy to interfere with severe hepatitis virus reinfection after woodchuck liver transplantation.. Transplantation 2004 Apr 15;77(7):965-72.
                    pubmed: 15087755doi: 10.1097/01.tp.0000113804.35096.8egoogle scholar: lookup
                  14. Soo YO, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KK, Ng MH, Chan P, Cheng G, Sung JJ. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients.. Clin Microbiol Infect 2004 Jul;10(7):676-8.
                    pmc: PMC7129386pubmed: 15214887doi: 10.1111/j.1469-0691.2004.00956.xgoogle scholar: lookup
                  15. Subbarao K, McAuliffe J, Vogel L, Fahle G, Fischer S, Tatti K, Packard M, Shieh WJ, Zaki S, Murphy B. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice.. J Virol 2004 Apr;78(7):3572-7.
                    pmc: PMC371090pubmed: 15016880doi: 10.1128/jvi.78.7.3572-3577.2004google scholar: lookup
                  16. Lang J, Attanath P, Quiambao B, Singhasivanon V, Chanthavanich P, Montalban C, Lutsch C, Pepin-Covatta S, Le Mener V, Miranda M, Sabchareon A. Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccine.. Acta Trop 1998 Jul 30;70(3):317-33.
                    pubmed: 9777717doi: 10.1016/s0001-706x(98)00038-2google scholar: lookup
                  17. Wang X, Ni B, Du X, Zhao G, Gao W, Shi X, Zhang S, Zhang L, Wang D, Luo D, Xing L, Jiang H, Li W, Jiang M, Mao L, He Y, Xiao Y, Wu Y. Protection of mammalian cells from severe acute respiratory syndrome coronavirus infection by equine neutralizing antibody.. Antivir Ther 2005;10(5):681-90.
                    pubmed: 16152762
                  18. Zhou L, Ni B, Luo D, Zhao G, Jia Z, Zhang L, Lin Z, Wang L, Zhang S, Xing L, Li J, Liang Y, Shi X, Zhao T, Zhou L, Wu Y, Wang X. Inhibition of infection caused by severe acute respiratory syndrome-associated coronavirus by equine neutralizing antibody in aged mice.. Int Immunopharmacol 2007 Mar;7(3):392-400.
                    pmc: PMC7106264pubmed: 17276898doi: 10.1016/j.intimp.2006.10.009google scholar: lookup
                  19. Zhao G, Ni B, Jiang H, Luo D, Pacal M, Zhou L, Zhang L, Xing L, Zhang L, Jia Z, Lin Z, Wang L, Li J, Liang Y, Shi X, Zhao T, Zhou L, Wu Y, Wang X. Inhibition of severe acute respiratory syndrome-associated coronavirus infection by equine neutralizing antibody in golden Syrian hamsters.. Viral Immunol 2007 Spring;20(1):197-205.
                    pubmed: 17425434doi: 10.1089/vim.2006.0064google scholar: lookup
                  20. Luo D, Ni B, Zhao G, Jia Z, Zhou L, Pacal M, Zhang L, Zhang S, Xing L, Lin Z, Wang L, Li J, Liang Y, Shi X, Zhao T, Zou L, Wu Y, Wang X. Protection from infection with severe acute respiratory syndrome coronavirus in a Chinese hamster model by equine neutralizing F(ab')2.. Viral Immunol 2007 Sep;20(3):495-502.
                    pubmed: 17931120doi: 10.1089/vim.2007.0038google scholar: lookup
                  21. Duan J, Yan X, Guo X, Cao W, Han W, Qi C, Feng J, Yang D, Gao G, Jin G. A human SARS-CoV neutralizing antibody against epitope on S2 protein.. Biochem Biophys Res Commun 2005 Jul 22;333(1):186-93.
                    pmc: PMC7092839pubmed: 15939399doi: 10.1016/j.bbrc.2005.05.089google scholar: lookup
                  22. Sui J, Li W, Roberts A, Matthews LJ, Murakami A, Vogel L, Wong SK, Subbarao K, Farzan M, Marasco WA. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants.. J Virol 2005 May;79(10):5900-6.
                    pmc: PMC1091676pubmed: 15857975doi: 10.1128/JVI.79.10.5900-5906.2005google scholar: lookup
                  23. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R, Lanzavecchia A. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus.. Nat Med 2004 Aug;10(8):871-5.
                    pmc: PMC7095806pubmed: 15247913doi: 10.1038/nm1080google scholar: lookup
                  24. Sui J, Li W, Murakami A, Tamin A, Matthews LJ, Wong SK, Moore MJ, Tallarico AS, Olurinde M, Choe H, Anderson LJ, Bellini WJ, Farzan M, Marasco WA. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association.. Proc Natl Acad Sci U S A 2004 Feb 24;101(8):2536-41.
                    pmc: PMC356985pubmed: 14983044doi: 10.1073/pnas.0307140101google scholar: lookup
                  25. ter Meulen J, Bakker AB, van den Brink EN, Weverling GJ, Martina BE, Haagmans BL, Kuiken T, de Kruif J, Preiser W, Spaan W, Gelderblom HR, Goudsmit J, Osterhaus AD. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets.. Lancet 2004 Jun 26;363(9427):2139-41.
                    pmc: PMC7112500pubmed: 15220038doi: 10.1016/S0140-6736(04)16506-9google scholar: lookup

                  Citations

                  This article has been cited 6 times.
                  1. León G, Herrera M, Vargas M, Arguedas M, Sánchez A, Segura Á, Gómez A, Solano G, Corrales-Aguilar E, Risner K, Narayanan A, Bailey C, Villalta M, Hernández A, Sánchez A, Cordero D, Solano D, Durán G, Segura E, Cerdas M, Umaña D, Moscoso E, Estrada R, Gutiérrez J, Méndez M, Castillo AC, Sánchez L, Sánchez R, Gutiérrez JM, Díaz C, Alape A. Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19.. Sci Rep 2021 May 10;11(1):9825.
                    doi: 10.1038/s41598-021-89242-zpubmed: 33972631google scholar: lookup
                  2. da Costa CBP, Martins FJ, da Cunha LER, Ratcliffe NA, Cisne de Paula R, Castro HC. COVID-19 and Hyperimmune sera: A feasible plan B to fight against coronavirus.. Int Immunopharmacol 2021 Jan;90:107220.
                    doi: 10.1016/j.intimp.2020.107220pubmed: 33302034google scholar: lookup
                  3. Song TZ, Zheng HY, Han JB, Jin L, Yang X, Liu FL, Luo RH, Tian RR, Cai HR, Feng XL, Liu C, Li MH, Zheng YT. Delayed severe cytokine storm and immune cell infiltration in SARS-CoV-2-infected aged Chinese rhesus macaques.. Zool Res 2020 Sep 18;41(5):503-516.
                    doi: 10.24272/j.issn.2095-8137.2020.202pubmed: 32772513google scholar: lookup
                  4. Santos WJ, Guiraldi LM, Lucheis SB. Should we be concerned about COVID-19 with nonhuman primates?. Am J Primatol 2020 Aug;82(8):e23158.
                    doi: 10.1002/ajp.23158pubmed: 32495390google scholar: lookup
                  5. White MR, Boland P, Tecle T, Gantz D, Sorenson G, Tornoe I, Holmskov U, McDonald B, Crouch EC, Hartshorn KL. Enhancement of antiviral activity of collectin trimers through cross-linking and mutagenesis of the carbohydrate recognition domain.. J Innate Immun 2010;2(3):267-79.
                    doi: 10.1159/000272313pubmed: 20375547google scholar: lookup
                  6. Cleri DJ, Ricketti AJ, Vernaleo JR. Severe acute respiratory syndrome (SARS).. Infect Dis Clin North Am 2010 Mar;24(1):175-202.
                    doi: 10.1016/j.idc.2009.10.005pubmed: 20171552google scholar: lookup
                  Subscribe to our newsletter
                  Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.